These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16286748)

  • 41. Topical hydroquinone in the treatment of some hyperpigmentary disorders.
    Amer M; Metwalli M
    Int J Dermatol; 1998 Jun; 37(6):449-50. PubMed ID: 9646135
    [No Abstract]   [Full Text] [Related]  

  • 42. Review of skin-lightening agents.
    Rendon MI; Gaviria JI
    Dermatol Surg; 2005 Jul; 31(7 Pt 2):886-9; discussion 889. PubMed ID: 16029683
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Unraveling the patterns of subclinical pheomelanin-enriched facial hyperpigmentation: effect of depigmenting agents.
    Hermanns JF; Petit L; Martalo O; Piérard-Franchimont C; Cauwenbergh G; Piérard GE
    Dermatology; 2000; 201(2):118-22. PubMed ID: 11053913
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reduction in the appearance of facial hyperpigmentation by topical N-acetyl glucosamine.
    Bissett DL; Robinson LR; Raleigh PS; Miyamoto K; Hakozaki T; Li J; Kelm GR
    J Cosmet Dermatol; 2007 Mar; 6(1):20-6. PubMed ID: 17348991
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A therapeutic strategy based on histological assessment of hyperpigmented skin lesions in Asians.
    Kurita M; Kato H; Yoshimura K
    J Plast Reconstr Aesthet Surg; 2009 Jul; 62(7):955-63. PubMed ID: 18456589
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Facial hyperpigmentation: causes and treatment.
    Vashi NA; Kundu RV
    Br J Dermatol; 2013 Oct; 169 Suppl 3():41-56. PubMed ID: 24098900
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A case of linear atrophoderma of Moulin successfully treated with methotrexate.
    Zaouak A; Ghorbel HH; Benmously-Mlika R; Koubaa W; Badri T; Fenniche S; Mokhtar I
    Dermatol Ther; 2014; 27(3):153-5. PubMed ID: 24903472
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Postinflammatory hyperpigmentation: A comprehensive overview: Treatment options and prevention.
    Chaowattanapanit S; Silpa-Archa N; Kohli I; Lim HW; Hamzavi I
    J Am Acad Dermatol; 2017 Oct; 77(4):607-621. PubMed ID: 28917452
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of topical treatment of pigmentation skin disorders with plant hydroquinone glucosides as assessed by quantitative color analysis.
    Clarys P; Barel A
    J Dermatol; 1998 Jun; 25(6):412-4. PubMed ID: 9675352
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reduction of facial redness with resveratrol added to topical product containing green tea polyphenols and caffeine.
    Ferzli G; Patel M; Phrsai N; Brody N
    J Drugs Dermatol; 2013 Jul; 12(7):770-4. PubMed ID: 23884488
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New and emerging treatments for hyperpigmentation.
    Alexis AF
    J Drugs Dermatol; 2014 Apr; 13(4):382-5. PubMed ID: 24719055
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Postinflammatory hyperpigmentation: evolving combination treatment strategies.
    Taylor SC; Burgess CM; Callender VD; Fu J; Rendon MI; Roberts WE; Shalita AR
    Cutis; 2006 Aug; 78(2 Suppl 2):6-19. PubMed ID: 16977792
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Depigmentation of brown Guinea pig skin by topical application of methimazole.
    Kasraee B
    J Invest Dermatol; 2002 Jan; 118(1):205-7. PubMed ID: 11851896
    [No Abstract]   [Full Text] [Related]  

  • 54. Assessment of topical hypopigmenting agents on solar lentigines of Asian women.
    Hermanns JF; Petit L; Piérard-Franchimont C; Paquet P; Piérard GE
    Dermatology; 2002; 204(4):281-6. PubMed ID: 12077522
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hyperpigmentation: types, diagnostics and targeted treatment options.
    Nieuweboer-Krobotova L
    J Eur Acad Dermatol Venereol; 2013 Jan; 27 Suppl 1():2-4. PubMed ID: 23205538
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Postinflammatory Hyperpigmentation: Epidemiology, Clinical Presentation, Pathogenesis and Treatment.
    Kaufman BP; Aman T; Alexis AF
    Am J Clin Dermatol; 2018 Aug; 19(4):489-503. PubMed ID: 29222629
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel formulations for topical delivery of tranexamic acid: assessing the need of epidermal targeting for hyperpigmentation disorders.
    Verma P; Yadav KS
    Expert Opin Drug Deliv; 2023 Jun; 20(6):773-783. PubMed ID: 37086183
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Medical makeup: the correction of hyperpigmentation disorders.
    Nonni J
    Ann Dermatol Venereol; 2012 Dec; 139 Suppl 4():S170-6. PubMed ID: 23522634
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dermocosmetic management of hyperpigmentations.
    Guerrero D
    Ann Dermatol Venereol; 2012 Dec; 139 Suppl 4():S166-9. PubMed ID: 23522633
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Histopathological Changes Induced by Malassezin: A Novel Natural Microbiome Indole for Treatment of Facial Hyperpigmentation.
    Grimes P; Bhawan J; Howell M; Desai S; Coryell E; Einziger M; Simpson A; Yaroshinsky A; McCraw T
    J Drugs Dermatol; 2022 Feb; 21(2):141-145. PubMed ID: 35133118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.